Blueprint Medicines (BPMC) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Blueprint Medicines Reports First Quarter 2019 Financial Results
May 9, 2019 7:00 AM EDTCAMBRIDGE, Mass., May 9, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the quarter ended March 31, 2019.
"Based on significant clinical and regulatory progress in the first quarter, we accelerated multiple programs and advanced our '2020 Blueprint' strategy to transform Blueprint Medicines into a... More
